$177MSeries A, 17 June 2025
Launched with a $177M Series A to develop first-in-class precision medicines for cancer.
- Amount
- $177M
- Stage
- Series A
- Announced
- 17 June 2025
- Lead
- Omega Funds
- Other investors
- Atlas Venture, Lightspeed Venture Partners, BVF Partners, Cormorant Asset Management
- Use of funds
- Launched with a $177M Series A to develop first-in-class precision medicines for cancer.
- Checked
- Amount and date checked against the press source
- Source
- Antares Therapeutics launches with $177M Series A (date approx) pulse2.com